Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
← catalyst calendarNCT07570654 · readout ≤ 834 d
Sponsored by COMPASS Pathways (industry) · CMPS — their whole pipeline →.
Phase
Phase 2/3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
300estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | Nov 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- PTSD - Post Traumatic Stress Disorder
- PTSD
- PTSD Symptoms
- PTSD, Post Traumatic Stress Disorder
Intervention
- Drug: COMP360 psilocybin
Primary outcome
what the primary-completion date above is the date OFCOMP360 25 mg versus COMP360 1 mg change from Baseline to Week 8 in CAPS-5 total severity score
measured 8 weeks
Permalink · CMPS's whole pipeline · Catalyst calendar · Every registered study · What changed